Increased PD ‐1/ PD ‐ L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never‐Smokers and Never‐Drinkers
Head & Neck · 2025
DOI: 10.1002/hed.27981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Mathias Fiedler und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Mouth Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to explore the disparities in PD‐1 and PD‐L1 expression among oral squamous cell carcinomas (OSCCs) in individuals categorized as never‐smokers/never‐drinkers versus smokers/drinkers.
Methods
Immunohistochemical staining for PD‐1 and PD‐L1, along with PDCD1LG2/cen9 dual color probe analysis, was conducted on 130 OSCC specimens from both smoker/drinker and never‐smoker/never‐drinker cohorts. Associations between smoking/drinking status, clinicopathologic data, immunohistochemical antibody expression, fluorescence in situ hybridization, and survival outcomes were assessed.
Results
OSCC in never‐smokers/never‐drinkers exhibited significantly elevated PD‐1 expression ( p = 0.003), increased PD‐L1‐TPS expression ( p = 0.044), and elevated PD‐L1‐CPS expression ( p < 0.001). High PD‐L1‐ICS expression was more prevalent in never‐smokers ( p = 0.042). Moreover, never‐smokers and never‐drinkers demonstrated augmented PD‐L1 gene copy numbers ( p = 0.081 and p = 0.054, respectively). Increased PD‐L1 gene copy number, particularly amplification, correlated with PD‐L1‐TPS ( p = 0.039 and p < 0.001). Conversely, PD‐L1 gene copy loss was associated with negative PD‐L1‐CPS ( p = 0.023). Notably, positive PD‐L1‐CPS was significantly linked with improved overall survival ( p = 0.023).
Conclusions
OSCC arising in never‐smokers/never‐drinkers exhibit heightened PD‐1/PD‐L1 signaling, suggesting potential efficacy of immune checkpoint therapy in this subgroup of tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.
- Institute of Pathology, University of Regensburg, Regensburg, Germany.
- Clinic of Gynecology and Obstetrics, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany.
- Department of Oral and Maxillofacial Surgery, Center for Medical Biotechnology, University Hospital Regensburg, Regensburg, Germany.
- Center of Tumor Registry, University of Regensburg, Regensburg, Germany.
ORCID-Profile: Mathias Fiedler, Tobias Ettl
Zitieren
APA
Fiedler, M., Off, A., Gärtner, A., Brockhoff, G., Eichberger, J., Gottsauner, M., Schuderer, J. G., Maurer, M., Bauer, R. J., Gerken, M., Reichert, T. E., Ettl, T., & Weber, F. (2025). Increased PD ‐1/ PD ‐ L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never‐Smokers and Never‐Drinkers. Head & Neck. https://doi.org/10.1002/hed.27981
Vancouver
Fiedler M, Off A, Gärtner A, Brockhoff G, Eichberger J, Gottsauner M, et al. Increased PD ‐1/ PD ‐ L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never‐Smokers and Never‐Drinkers. Head & Neck. 2025. doi:10.1002/hed.27981
BibTeX
@article{Fiedler2025,
author = {Fiedler, Mathias and Off, Alisa and Gärtner, Andreas and Brockhoff, Gero and Eichberger, Jonas and Gottsauner, Maximilian and Schuderer, Johannes G and Maurer, Michael and Bauer, Richard J and Gerken, Michael and Reichert, Torsten E and Ettl, Tobias and Weber, Florian},
title = {Increased PD ‐1/ PD ‐ L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never‐Smokers and Never‐Drinkers},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.27981}
}
EUVIMED